Seminoma screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
According to the '''KIT'' Mutations Are Common in Testicular Seminomas' study, [[Screening (medicine)|screening]] for seminoma by using the highly sensitive combination of denaturing [[High performance liquid chromatography|high performance liquid chromatography (HPLC)]] and direct [[sequencing]]. | |||
According to the [ | |||
==Screening== | ==Screening== | ||
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with: | According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with: | ||
* | *Mutations of KIT exon 17 | ||
* | *D816H mutation | ||
* | *Y823D mutation | ||
Revision as of 16:51, 9 May 2019
|
Seminoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Seminoma screening On the Web |
|
American Roentgen Ray Society Images of Seminoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
According to the 'KIT Mutations Are Common in Testicular Seminomas' study, screening for seminoma by using the highly sensitive combination of denaturing high performance liquid chromatography (HPLC) and direct sequencing.
Screening
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- Mutations of KIT exon 17
- D816H mutation
- Y823D mutation
References
[[Category:Oncology]